UTH.F - United Therapeutics Corporation
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 204.50 |
| Open | 203.80 |
| Bid | 0.00 x 30000 |
| Ask | 0.00 x 30000 |
| Day's Range | 203.80 - 210.00 |
| 52 Week Range | 189.80 - 271.40 |
| Volume | |
| Avg. Volume | 5 |
| Market Cap | 9.991B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 14.27 |
| EPS (TTM) | 14.72 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 231.89 |
Fair Value
Related Research
ZacksWhy Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider Monkey14 Best Biotech Stocks To Buy According To Hedge Funds
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
Insider MonkeyBillionaire Jim Simons’ 2023 Portfolio: Top 15 Stock Picks
In this article, we discuss billionaire Jim Simons’ top 15 stock picks in 2023. If you want to see more stocks in this selection, check out Billionaire Jim Simons’ 2023 Portfolio: Top 5 Stock Picks. Managed by Renaissance Technologies, the Medallion Fund stands as one of the world’s most prosperous and enigmatic hedge funds. Established […]
ZacksUnited Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.
- Thomson Reuters StreetEvents
Q1 2023 United Therapeutics Corp Earnings Call
Q1 2023 United Therapeutics Corp Earnings Call
BenzingaWhy United Therapeutics Shares Are Falling Today
United Therapeutics Corporation's (NASDAQ: UTHR) Q1 revenues grew 10% Y/Y to $506.9 million, missing the consensus of $510.77 million. The company reported Q1 EPS of $4.86, beating the consensus of $4.47. Net product sales from treprostinil-based products grew by 16% Y/Y. The growth in Tyvaso revenues resulted primarily from an increase in quantities sold driven by the launch of sales of Tyvaso DPI in June 2022. "We are extremely pleased with the underlying strength of our Tyvaso franchise, high
ZacksHere's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings
The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksUnited Therapeutics (UTHR) Q1 Earnings Beat Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., May 03, 2023--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.
ZacksRelay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2023--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023.
Simply Wall St.United Therapeutics Corporation's (NASDAQ:UTHR) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has...
InvestorPlace7 Biotech Stocks That Could Cure Your Portfolio Woes
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms). Therefore, finding a cure would translate to a massive economic boon. On a related note, society eagerly anticipates these breakthroughs. Therefore, biotech stocks
- Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 18, 2023--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its development portfolio will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 43rd Annual Meeting and Scientific Sessions in Denver, Colorado on April 19-22, 2023, and at the American Thoracic Society (ATS) International Conference in Washington, D.C. on May 19-24, 2023. A
- Simply Wall St.
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
ZacksUnited Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 06, 2023--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 33rd Annual Healthcare Conference.
- Business Wire
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 28, 2023--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston.
ZacksUnited Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.
Insider Monkey13 High Growth Pharma Stocks that are Profitable
In this piece, we will take a look at 13 high growth pharma stocks that are profitable. For more stocks, head on over to 5 High Growth Pharma Stocks that are Profitable. One industry that has rapidly evolved with time and impacted millions, if not billions, of lives is the pharmaceutical sector. Within a hundred […]
- Simply Wall St.
United Therapeutics Full Year 2022 Earnings: Misses Expectations
United Therapeutics ( NASDAQ:UTHR ) Full Year 2022 Results Key Financial Results Revenue: US$1.94b (up 15% from FY...
ZacksUnited Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 22, 2023--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2022.